# Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma

> **NCT01283048** · PHASE1 · COMPLETED · sponsor: **Toni Choueiri, MD** · enrollment: 32 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** BKM-120 Bevacizumab

## Key facts

- **NCT ID:** NCT01283048
- **Lead sponsor:** Toni Choueiri, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2016-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01283048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01283048, "Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01283048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*